Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Wrinkle In NDI Debate: Supplement Ingredients Used As Drugs Outside US

This article was originally published in The Tan Sheet

Executive Summary

Senator McCaskill asks FDA to halt sales of supplements containing vinpocetine and picamilion after research, led by an advocate for tighter regulation of supplement manufacturing, shows the ingredients are not derived from natural sources but are synthetic and used as drugs in other countries.

You may also be interested in...

FDA Opens Extra-Regulatory Enforcement Door On Vinpocetine – CRN, NPA

The Council for Responsible Nutrition and the Natural Products Association argue in comments that FDA would establish a process for removing ingredients from the marketplace outside its regulatory authority if it follows on its proposal to remove vinpocetine, currently widely used in supplements.

Hatch Questions FDA Motive, Process In Proposed Vinpocetine Ban

Hatch, primary author of the legislation Congress passed in 1994 as FDA's framework for regulating the supplement industry, notes in a letter that FDA did not question vinpocetine's safety in evaluations of five NDI notifications.

FDA Finds Ingredient's IND Past After Signing Off For Supplement Use

Supplement industry stakeholders say FDA makes an unjustifiable regulatory move by stating that the widely used dietary supplement ingredient is noncompliant, while the finding compels the agency to reverse its earlier acceptance of NDI notifications for vinpocetine.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts